Government advice regarding the implementation of vaccination policy Oct 2021-March 2022.
Colin Whiting made this Official Information request to Crown Law Office
This request has an unknown status. We're waiting for Colin Whiting to read a recent response and update the status.
From: Colin Whiting
Dear Crown Law Office,
I request all of the Government advice given by Crown Law, to all Government agencies regarding the implementation of vaccination policy from 1st October 2021 until 31st March 2022.
Yours faithfully,
Colin Whiting
From: OIA
Crown Law Office
Kia ora Colin,
We acknowledge receipt of your email of 30 June 2025 requesting
information under the Official Information Act 1982.
In accordance with section 15 of the Official Information Act, a response
to your request will be provided as soon as is reasonably practicable, and
in any case within 20 working days of receipt of your request, i.e. by 28
July 2025.
Ngā mihi nui | Kind regards
Te Tari Ture o te Karauna Crown Law Office
19 Aitken Street | PO Box 2858 | Wellington 6011
[1]A picture containing text Description automatically generated
show quoted sections
From: OIA
Crown Law Office
Kia ora Colin
Please see attached for the response to your Official Information Act
request of 30 June 2025.
Kind regards | Ngā mihi nui
Te Tari Ture o te Karauna Crown Law Office
19 Aitken Street | PO Box 2858 | Wellington 6011
[1]A picture containing text Description automatically generated
show quoted sections
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence
SPENCER JONES left an annotation ()
International Journal of Vaccine Theory, Practice, and Research 4(1)
https://doi.org/10.56098/hqjnk479
From Innovation to Inquiry — COVID -19 mRNA
Vaccination and Its Global Consequences —
with Special Reference to New Zealand
Bruce Rapley, PhD
Consultant and Independent Researcher, Smart Technology, New Zealand;
Abstract
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief
among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by
institutional consensus, and expedited regulatory pathways. Subsequent developments revealed
questions regarding safety, ethics, efficacy, and governance. This formal review, with specific
reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed
under Emergency Use Authorizations. A range of post-deployment signals, including immunological
anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain
insufficiently investigated. Regulatory responses have not met the standard of precaution typically
applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-
prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-
COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date,
no national authority has published comprehensive disaggregated mortality data by vaccination
status.
Keywords: adverse events, COVID-19 vaccination, Emergency Use Authorization, EUA, genetic engineering, IgG4 class
switching, mRNA vaccination, plasmid DNA, post-market surveillance, therapeutic suppression, ivermectin, spike protein toxicity,
regulatory oversight failure, scientific censorship, turbo cancer, vaccine-induced thrombotic thrombocytopenia, VITT
Link to this